CDDEP SOWA Dashboard Sample Pages

The State of the World’s Antibiotics, 2020 Country Dashboards on policy, antimicrobial resistance, antimicrobial use, and public health indicators.

© Center for Disease Dynamics, Economics & Policy (CDDEP), 2020.

Template design by Tolpa Studios, www.tolpa.com.

Reproduction is authorized provided the source is acknowledged.

The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of CDDEP. Related research and additional information on access to antibiotics and antibiotic use and resistance is available at www.cddep.org.

Suggested Citation:

CENTER FOR DISEASE DYNAMICS, ECONOMICS & POLICY 1400 Eye Street, NW Suite 500 Washington DC 20005 USA

The State of the World’s Antibiotics, 2020 Country Dashboards on policy, antimicrobial resistance, antimicrobial use, and public health indicators.

Editors Dr. Geetanjali Kapoor Aditi Sriram Ramanan Laxminarayan

Table of Contents Foreword

1

06

Foreword This is dummy copy. It is not meant to be read. It has been placed here solely to demonstrate the look and feel of finished, typeset text. Only for show. He who searches for meaning here will be sorely disappointed. These words are here to provide the reader with a basic impression of how actual text will appear in its final presentation. Think of them merely as actors on a paper stage, in a performance devoid of content yet rich in form. That being the case, there is really no point in your continuing to read them. After all, you have many other things you should be doing. Who's paying you to waste this time, anyway?

This is dummy copy. It's Greek to you. Unless, of course, you're Greek, in which case, it really makes no sense. Why, you can't even read it! It is strictly for mock-ups. You may mock it up as strictly as you wish.

Meaningless mock-up, mock turtle soup spilled on a mock turtle neck. Mach I Convertible copy. To kill a mockingbird, you need only force it to read this copy. This is Meaningless filler. (Elvis movies.)

It is not meant to be a forum for value judgments nor a scholarly diatribe on how virtue should be measured. The whole point here (if such a claim can be made in an admittedly pointless paragraph) is that this is dummy copy. Real bullets explode with destructive intensity. Such is not the case with dummy bullets. In fact, they don't explode at all. Duds. Dull thuds. Dudley do-wrongs. And dowrongs don't make a right. Why on earth are you still reading this? Haven't you realized it's just dummy copy? How many times must you be reminded that it's really not meant to be read? You're only wasting precious time. But be that as it may, you've got to throw in a short paragraph from time to time. Here's a short paragraph.

It breaks up the intimidating blocks of text and makes the page more inviting to read, which is again ironic, considering this is dummy copy. It is not meant to be read. Someday this space will be occupied by real copy that is meant to be read. What other form of filler would dare be so politically incorrect? This is dummy copy. It is not meant to be read. Good thing.

07

CDDEP Dashboards

Argentina Latin America & Caribbean | Upper-middle income

Policy Indicators Enrolment in Global An microbial Resistance Surveillance System (GLASS)

Na onal Ac on Plan on AMR (NAP) Published

Surveillance: Human Use

Surveillance: Animal Use

Surveillance: Human Resistance

Surveillance: Animal Resistance

An microbial Resistance Indicators

Humans

of isolates 45.29% tested

isolates 20.98% oftested

of isolates 20.39% tested

MRSA

CRE

ESBL

Carbapenem-resistant Klebsiella pneumoniae

Methicillin-resistant Staphylococcus aureus

3G cephalosporin-resistant Escherichia coli

n/a

n/a

DRI

DRI

Drug Resistance Index for WHO Cri cal pathogens 2020

Drug Resistance Index for MRSA, CRE, and ESBL 2020

Note: a) Resistance rates presented include intermediate resistant isolates. b) The Drug Resistance Index (DRI) is an aggregate measure that combines anbioc use and resistance into a single metric with 0 indica ng that all included pathogens were treatable by the drugs considered and 100 indicang none were treatable. c) WHO cri cal pathogens are carbapenem-resistant enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, & carbapenem-resistant Pseudomonas aeruginosa.

Animals Salmonella spp.

Ampicillin Ciprofoxacin Colis n Tetracycline

08

E.coli

0 0 0 0

Ampicillin Ciprofoxacin Colis n Tetracycline

25% n/a 49% 22.5%

CDDEP Dashboards

Argentina An microbial Use Indicators

Humans Total Use, 2010 (DDDs in Mill)

243

Per Capita Use, 2010 (DDD)

5.91

Total Use, 2020 (DDDs in Mill)

338

Per Capita Use, 2020 (DDD)

7.43

Change in total use, 2010-20 (DDDs in Mill)

94.36

Change in per capita use, 2010-20 (DDD)

1.52

% Change in total use, 2010-20

38.72%

% Change in per capita use, 2010-2020

25.63%

Global average of % change in total use, 2010-20

0.74%

Global average of % change in per capita use, 2010-20

0.35%

Regional average of % change in total use, 2010-20

0.26%

Regional average of % change in per capita use, 2010-20

0.12%

Animals Total Use, 2013 (Tons)

1348.90

Total Use, 2030 (Tons)

1619.04

mg/PCU, 2013

48.44

mg/PCU, 2030

49.92

Public Health Indicators DTP3

86

HepB3

86

Hib3

86

PCV3

88 80

RotaC 0

20

40

60

8.2

Infant Mortality Rate per 1000 live births

124.22

Under-ďŹ ve deaths from diarrheal diseases

12.93 Under-ďŹ ve pneumococcal death rate per 100,000 children

27

Incidence of tuberculosis per 100,000 people

99.08

96.77

n/a

Access to improved drinking water source (%)

Access to improved sanita on facili es (%)

Access to basic handwashing facili es including soap and water (%)

80 100

% of children vaccinated Data from latest year

9.12% Current health expenditure % of GDP

4.0

2.6

Physicians per 1000 people

Nurses and midwives per 1000 people

16.05% Domes c general government health expenditure % of general government expenditure

15.02% $ 1324.60 Out-of-pocket expenditure % of current health expenditure

Current health expenditure per capita

09

CDDEP Dashboards

Australia East Asia & PaciďŹ c | High income

Policy Indicators Enrolment in Global An microbial Resistance Surveillance System (GLASS)

Na onal Ac on Plan on AMR (NAP) Published

Surveillance: Human Use

Surveillance: Animal Use

Surveillance: Human Resistance

Surveillance: Animal Resistance

An microbial Resistance Indicators

Humans

of isolates 19.01% tested

0.80%

MRSA

CRE

Methicillin-resistant Staphylococcus aureus

of isolates tested

of isolates 11.32% tested

ESBL

Carbapenem-resistant Klebsiella pneumoniae

3G cephalosporin-resistant Escherichia coli

n/a

n/a

DRI

DRI

Drug Resistance Index for WHO Cri cal pathogens 2020

Drug Resistance Index for MRSA, CRE, and ESBL 2020

Note: a) Resistance rates presented include intermediate resistant isolates. b) The Drug Resistance Index (DRI) is an aggregate measure that combines anbioc use and resistance into a single metric with 0 indica ng that all included pathogens were treatable by the drugs considered and 100 indicang none were treatable. c) WHO cri cal pathogens are carbapenem-resistant enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, & carbapenem-resistant Pseudomonas aeruginosa.

Animals Salmonella spp.

Ampicillin Ciprofoxacin Colis n Tetracycline

10

n/a n/a n/a n/a

E.coli Ampicillin Ciprofoxacin Colis n Tetracycline

n/a n/a n/a n/a

CDDEP Dashboards

Australia An microbial Use Indicators

Humans Total Use, 2010 (DDDs in Mill)

238

Per Capita Use, 2010 (DDD)

10.84

Total Use, 2020 (DDDs in Mill)

289

Per Capita Use, 2020 (DDD)

11.40

Change in total use, 2010-20 (DDDs in Mill)

50.29

Change in per capita use, 2010-20 (DDD)

0.56

% Change in total use, 2010-20

21.05%

% Change in per capita use, 2010-2020

5.17%

Global average of % change in total use, 2010-20

0.74%

Global average of % change in per capita use, 2010-20

0.35%

Regional average of % change in total use, 2010-20

1.59%

Regional average of % change in per capita use, 2010-20

1.40%

Animals Total Use, 2013 (Tons)

305.1

Total Use, 2030 (Tons)

362.76

mg/PCU, 2013

12.72

mg/PCU, 2030

15.51

Public Health Indicators DTP3

95

HepB3

95

Hib3

95

PCV3

96 87

RotaC 0

20

40

60

3.1

Infant Mortality Rate per 1000 live births

9.92

Under-ďŹ ve deaths from diarrheal diseases

2.27 Under-ďŹ ve pneumococcal death rate per 100,000 children

6.6

Incidence of tuberculosis per 100,000 people

99.97

99.99

n/a

Access to improved drinking water source (%)

Access to improved sanita on facili es (%)

Access to basic handwashing facili es including soap and water (%)

80 100

% of children vaccinated Data from latest year

9.21% Current health expenditure % of GDP

3.6

12.7

Physicians per 1000 people

Nurses and midwives per 1000 people

17.80% Domes c general government health expenditure % of general government expenditure

18.15% $ 5331.82 Out-of-pocket expenditure % of current health expenditure

Current health expenditure per capita

11